Blood coagulation testing of pregnant women with hypertension can be reduced

Abstract BACKGROUND There are radiographic and clinical outcome differences between patients with deep and lobar intracerebral hemorrhage (ICH) locations. Pilot studies suggest that there may be functional coagulation differences between these locations detectable using whole blood coagulation testing. OBJECTIVE To confirm the presence of interlocation functional coagulation differences using a larger cohort of deep and lobar ICH patients receiving whole blood coagulation testing: thromboelastography (TEG; Haemonetics). METHODS Clinical and laboratory data were prospectively collected between 2009 and 2018 for primary ICH patients admitted to a tertiary referral medical center. Deep and lobar ICH patients receiving admission TEG were analyzed. Patients with preceding anticoagulant use and/or admission coagulopathy (using prothrombin time/partial thromboplastin time/platelet count) were excluded. Linear regression models assessed the association of ICH location (independent variable) with TEG and traditional plasma coagulation test results (dependent variable) after adjusting for baseline hematoma size, age, sex, and stroke severity. RESULTS We identified 154 deep and 53 lobar ICH patients who received TEG. Deep ICH patients were younger and had smaller admission hematoma volumes (median: 16 vs 29 mL). Adjusted multivariable linear regression analysis revealed longer TEG R times (0.57 min; 95% CI: 0.02-1.11; P = .04), indicating longer clot formation times, in deep compared to lobar ICH. No other TEG parameter or plasma-based coagulation differences were seen. CONCLUSION We identified longer clot formation times, suggesting relative coagulopathy in deep compared to lobar ICH confirming results from prior work. Further work is required to elucidate mechanisms for these differences and whether ICH location should be considered in future coagulopathy treatment paradigms for ICH.

Download Full-text

P33 Whole blood coagulation thrombelastometry (ROTEM®) profile in 19 pregnant women

Thrombosis Research ◽

10.1016/s0049-3848(09)70078-7 ◽

2009 ◽

Vol 123 ◽

pp. S148-S149

Author(s):

L. Spiezia ◽

E. Stocco ◽

E. Campello ◽

V. Rossetto ◽

D. Bertini ◽

...

Keyword(s):

Pregnant Women ◽

Blood Coagulation ◽

Whole Blood

Download Full-text

Evaluation of the blood coagulation system in pregnant women with placental insufficiency and their newborns

Rossiiskii vestnik akushera-ginekologa ◽

10.17116/rosakush20171719-13 ◽

2017 ◽

Vol 17 (1) ◽

pp. 9

Author(s):

N. V. Putilova ◽

E. A. Nesterova ◽

L. A. Pestryaeva

Keyword(s):

Pregnant Women ◽

Blood Coagulation ◽

Placental Insufficiency ◽

Coagulation System ◽

Blood Coagulation System

Download Full-text

The effects of fructose diphosphate on routine coagulation tests in vitro

Scientific Reports ◽

10.1038/s41598-021-04263-y ◽

2022 ◽

Vol 12 (1) ◽

Author(s):

Tongqing Chen ◽

Duan Chen ◽

Lu Chen ◽

Zhengxu Chen ◽

Baolong Wang ◽

...

Keyword(s):

Platelet Aggregation ◽

Blood Coagulation ◽

Detection System ◽

Coagulation System ◽

Thrombin Time ◽

Aggregation Rate ◽

Coagulation Testing ◽

Coagulation Tests ◽

Routine Coagulation

AbstractTo evaluate the effects of fructose diphosphate (FDP) on routine coagulation tests in vitro, we added FDP into the mixed normal plasma to obtain the final concentration of 0, 1, 2, 3, 4, 5, 6, 10, 15, 20, 25, 30 and 35 mg/mL of drug. Prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen (FBG) and thrombin time (TT) of samples were analyzed with blood coagulation analyzers from four different manufacturers(Sysmex, Stago, SEKISUI and Werfen) and their corresponding reagents, respectively. Before the experiment, we also observed whether there were significant differences in coagulation test results of different lots of reagents produced by each manufacturer. At the same time as the four routine clotting tests, the Sysmex blood coagulation analyzer and its proprietary analysis software were used to detect the change of maximum platelet aggregation rate in platelet-rich plasma after adding FDP (0, 1, 2, 3, 4, 5 and 6 mg/mL). The results of PT, aPTT and TT showed a FDP (0–35 mg/mL) concentration-dependent increase and a FBG concentration-dependent decrease. The degree of change (increase or decrease) varied depending on the assay system, with PT and aPTT being more affected by the Sysmex blood coagulation testing instrument reagent system and less affected by CEKISUI, TT less affected by CEKISUI and more affected by Stago, and FBG less affected by Stago and more affected by Sysmex. The results of PT, aPTT and TT were statistically positively correlated with their FDP concentrations, while FBG was negatively correlated. The correlation coefficients between FDP and the coagulation testing systems of Sysmex, Stago, Werfen and SEKISUI were 0.975, 0.988, 0.967, 0.986 for PT, and 0.993, 0.989, 0.990 and 0.962 for aPTT, 0.994, 0.960, 0.977 and 0.982 for TT, − 0.990, − 0.983, − 0.989 and − 0.954 for FBG, respectively. Different concentrations of FDP (0, 1, 2, 3, 4, 5 and 6 mg/mL) had different effects on the maximum aggregation rate of platelet induced by the agonists of adenosine diphosphate (ADP, 5 µmol/L), arachidonic acid (Ara, 1 mmol/L), collagen (Col, 2.5 µg/mL) and epinephrine (Epi,10 µmol/L), but the overall downward trend was consistent, that is, with the increase of FDP concentration, the platelet aggregation rate decreased significantly. Our experimental study demonstrated a possible effect of FDP on the assays of coagulation and Platelet aggregation, which may arise because the drug interferes with the coagulation and platelet aggregation detection system, or it may affect our in vivo coagulation system and Platelet aggregation function, the real mechanism of which remains to be further verified and studied.

Download Full-text

Effect of Heparin on Antithrombin III Activity During Delivery and Early Puerperium

10.1055/s-0039-1689222 ◽

1975 ◽

Author(s):

I. Rákóczi ◽

B. Garadnay ◽

L. Arnold ◽

I. Gáti

Keyword(s):

Pregnant Women ◽

Blood Coagulation ◽

Antithrombin Iii ◽

Modified Method ◽

Heparin Treatment ◽

At Iii ◽

Antithrombin Iii Activity

It is known that antithrombin III (AT III) is the main inhibitor of blood coagulation. It inactivates thrombin and activated × factor. Heparin increases the AT III activity in vitro as well as in vivo. The authors have studied the AT III activity in sera of 30 pregnant women, at term, before labour started (2–24 hrs) and 30 as well as 60 min after the birth of placenta and daily for five days after delivery. The AT III activity was determined using the modified method of Gerendas. Out of the 30 women 15 were given 5000 IU heparin subcutaneously 1½—2 hours before delivery. In the 15 women with no heparin treatment AT III activity of serum significantly decreased after birth of placenta compared with the predelivery value and became normal on the fifth postpartum day. Heparin given subcutaneously prevented development of this decrease.

Download Full-text

Blood Coagulation Testing Smartphone Platform Using Quartz Crystal Microbalance Dissipation Method

Sensors ◽

10.3390/s18093073 ◽

2018 ◽

Vol 18 (9) ◽

pp. 3073 ◽

Cited By ~ 3

Author(s):

Jia Yao ◽

Bin Feng ◽

Zhiqi Zhang ◽

Chuanyu Li ◽

Wei Zhang ◽

...

Keyword(s):

Blood Coagulation ◽

Quartz Crystal Microbalance ◽

Quartz Crystal ◽

Clinical Laboratory ◽

Point Of Care ◽

Dissipation Factor ◽

Parylene C ◽

Adhesive Surface ◽

Self Testing ◽

Coagulation Testing

Blood coagulation function monitoring is important for people who are receiving anticoagulation treatment and a portable device is needed by these patients for blood coagulation self-testing. In this paper, a novel smartphone based blood coagulation test platform was proposed. It was developed based on parylene-C coated quartz crystal microbalance (QCM) dissipation measuring and analysis. The parylene-C coating constructed a robust and adhesive surface for fibrin capturing. The dissipation factor was obtained by measuring the frequency response of the sensor. All measured data were sent to a smartphone via Bluetooth for dissipation calculation and blood coagulation results computation. Two major coagulation indexes, activated partial thromboplastin time (APTT) and prothrombin time (PT) were measured on this platform compared with results by a commercial hemostasis system in a clinical laboratory. The measurement results showed that the adjusted R-square (R2) value for APTT and PT measurements were 0.985 and 0.961 respectively. The QCM dissipation method for blood coagulation measurement was reliable and effective and the platform together with the QCM dissipation method was a promising solution for point of care blood coagulation testing.

Download Full-text

Comparative analysis of the results of non-activated thromboelastometry and thromboelastography of venous blood in pregnant women in health and disease

Тромбоз, гемостаз и реология ◽

10.25555/thr.2021.2.0973 ◽

2021 ◽

Author(s):

Л.А. Пестряева ◽

С.В. Кинжалова ◽

Н.В. Путилова ◽

С.В. Борисова

Keyword(s):

Comparative Analysis ◽

Pregnant Women ◽

Blood Coagulation ◽

Main Group ◽

Coagulation System ◽

Control Group ◽

Blood Coagulation Disorders ◽

Fibrinogen Concentration ◽

Reference Ranges ◽

Thrombin Time

Цель исследования: сравнительный анализ неактивированной тромбоэластографии (ТЭГ) и тромбоэластометрии (ТЭМ) в диагностике нарушений свертывающей системы крови при беременности. Материалы и методы. Обследованы 2 группы женщин в III триместре беременности: 44 женщины с привычным невынашиванием беременности в анамнезе (основная группа) и 35 условно здоровых беременных (контрольная группа). Пациентки основной группы получали профилактику тромботических осложнений низкомолекулярными гепаринами (НМГ). Выполнено стандартное исследование свертывающей системы крови: подсчет тромбоцитов, определение концентрации фибриногена, протромбинового времени (ПТ) по Квику, активированного частичного тромбопластинового времени (АЧТВ), тромбинового времени (ТВ), неактивированная ТЭГ и ТЭМ. Результаты. Значимых различий в значениях фибриногена, АЧТВ, ПТ между группами выявлено не было. В обеих группах при ТЭГ/ТЭМ исследовании установлено укорочение интервалов времени свертывания и времени образования сгустка, увеличение плотности сгустка, что соответствует протромботическим изменениям системы гемостаза при беременности. Определены значения показателей неактивированной ТЭГ/ТЭМ в III триместре физиологически протекающей беременности. Заключение. Методы неактивированной ТЭГ и ТЭМ имеют высокую информативность в диагностике нарушений системы гемостаза и могут быть использованы для контроля состояния свертывающей системы крови при беременности наряду с активированными стандартизованными тестами. Objectives: to conduct a comparative analysis of non-activated thromboelastography (TEG) and thromboelastometry (TEM) in the diagnosis of blood coagulation disorders during pregnancy. Patients/Methods. We examined 2 groups of women in III trimester of pregnancy: 44 women with a history of habitual miscarriage (the main group) and 35 relatively healthy pregnant women (the control group). Patients of the main group received prophylaxis of thrombotic complications with low molecular weight heparins (LMWH). A standard study of the blood coagulation system with platelet count, determination of fibrinogen concentration, prothrombin time (PT) by Quick, activated partial thromboplastin time (APTT), thrombin time (TT), non-activated thromboelastography (TЕG) and thromboelastometry (TEM) was performed. Results. There were no signifi cant differences in fi brinogen level, APTT, PT between the groups. In both groups, TEG/TEM study found shortening of the clotting time intervals and clot formation time, an increase in clot density, which corresponds to hemostasis prothrombotic changes during pregnancy. Reference ranges of nonactivated TEG/TEM parameters in III trimester of physiological pregnancy were determined. Conclusions. Methods of non-activated TEG/TEM are highly informative in the diagnosis of hemostasis disorders and can be used, together with activated standardized tests, to monitor blood coagulation during pregnancy.

Download Full-text